Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
4/10/23 A Free

Executive/Senior Manager

400,000 0.6684%
2/1/23 A Free

Chief Technology Officer

400,000 0.6686%
2/1/23 A Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
-3.30%+1.19%+54.62%+104.15% 71.94B
+0.93%-3.31%+39.69%+76.57% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
-0.55%+1.15%-10.48%+370.81% 26.54B
-0.49%+2.80%+0.68%-4.24% 24.93B
+0.31%+1.33%+23.62%-9.16% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
-0.04%+0.22%+51.18%+167.93% 14.36B
Average -1.59%-0.12%+36.73%+172.46% 30.46B
Weighted average by Cap. -0.61%-0.24%+37.29%+133.36%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock